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journal homepage: www.aidm-onl ine.comEDITORIALHow sensitive is fecal immunochemical
testing in detecting colorectal neoplasms?The fecal immunochemical test (FIT) is increasingly being
adopted as the preferred testing strategy for the pre-
vention of colorectal cancer (CRC). The FIT has a user-
friendly design, and previous studies conducted in Taiwan
have confirmed that it is effective in detecting CRC with a
sensitivity of about 80% [1]. In addition, because the FIT
result is not affected by upper gastrointestinal lesions, its
specificity is high [2], which can substantially decrease
the risk of false-positive results and unnecessary colo-
noscopy [3]. Considering both sensitivity and specificity,
the area under the receiver operating characteristic curve
in predicting CRC has been estimated to be 83%, which
can be improved only minimally by adding conventional
risk factors into the prediction model [4]. Furthermore, a
recent meta-analysis including 19 diagnostic accuracy
studies on asymptomatic, average-risk adults from
different countries has shown consistently that the pooled
sensitivity, specificity, positive likelihood ratio, and
negative likelihood ratio of the FITs for CRC are 79%, 94%,
13.10, and 0.23, respectively, with an overall diagnostic
accuracy of 95% [5]. In the current issue of Advances in
Digestive Medicine, Chen et al [6] reported a diagnostic
accuracy study in a health check-up screening center, inSensitivityZ1 Interval cancer rate after a negative FIT and before the date of the next screening
The expected cancer incidence in the absence of screeningwhich they evaluated the performance of the FIT. They
found a sensitivity of 69.2% and specificity of 96.4% for
CRC, which lent support to the current evidence in
adopting FIT as a sensitive tool for mass screening; how-
ever, in order to generalize their findings and interpre-
tation to community-based mass screening, several issues
must be considered.http://dx.doi.org/10.1016/j.aidm.2014.05.001
2351-9797/Copyright ª 2014, The Gastroenterological Society of Taiw
Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.Health check-up setting versus community
setting
Diagnostic accuracy studies in the health check-up setting
consider the results of colonoscopy as well as FIT, so the
test sensitivity can be estimated as follows:
SensitivityZ
Number of positive FITs in participantswithCRC
Total number of CRCs in screening participants
However, whether this estimate would be applicable to a
community-based screening program is questionable. In
fact, between these two settings, there are several differ-
ences with respect to the evaluation of FIT performance.
First, from a methodological viewpoint, those whose FIT
results are negative do not undergo colonoscopy in the
community-based screening. Therefore, to estimate the
sensitivity of FIT in the community, we need to assume that
the number of CRC cases clinically diagnosed during the
screening interval (i.e., interval cancer) is an estimate of the
number of CRC cases missed by the first screen. Through the
collection of interval cancer cases from the Cancer Registry,
the sensitivity of FIT can be estimated as follows:This is the so-called proportional incidence method,
which is related to the length of the screening interval
(screening characteristic) as well as the length of the pre-
clinical detectable phase of CRC (biological characteristic)
[7]. This estimate will be more reflective of the true per-
formance of FIT seen in the community-based screening
program because, in this real-life setting, as well as in thean and The Digestive Endoscopy Society of Taiwan. Published by
70 Editorialhealth check-up setting, every element of the screening
process cannot be controlled. These elements may include
the delivery of FIT; adherence to FIT; stability of hemo-
globin during sampling, transport, and storage prior to
analysis; quality of laboratory measurement; adherence to
referral recommendations, given a positive FIT; and quality
of the colonoscopic procedure.
Using adherence as an example, in the health check-up
setting, individuals who do not comply with the screening
protocol are usually excluded from analysis. By contrast, in
the community setting, for a number of reasons, people
often either fail to adhere to the recommended FIT for CRC
screening or do not comply with colonoscopy when their
FITs are positive; however, we cannot exclude them from
analyses. Therefore, in addition to evaluating the accuracy
of FIT, it is crucial to pay attention to how well patients
adhere to the program. The relationship between test
sensitivity and sensitivity of a program can be expressed as
follows:
Sensitivity of a programZ test sensitivity adherence
Lower adherence will result in a lower sensitivity of the
screening program in detecting CRC, even when a highly
sensitive test is used.
Second, from a clinical standpoint, it is well known
that detectability of FIT is associated with the stage of
the cancer. In a recent study from Taiwan, researchers
have found that FIT showed a lower sensitivity in the
detection of carcinoma in situ and T1 cancer (67%) than
that in the detection of T2eT4 cancers (100%) [1]. The
cancer-stage-specific distribution in health-check-up







 ðvolume of the device buffer in mLÞ
ðmass of feces collected in mgÞcompared with that of the general average-risk popula-
tion [2,3,6].
CRC versus adenoma
Compared with CRC, colonic adenomas are much less likely
to bleed, and thus are less detectable by FIT. Diagnostic
accuracy studies that define a colonic adenoma as an index
lesion usually yield misleading results, as the sensitivity of
FIT will be very low. In the present study, the positive
likelihood ratio (i.e., sensitivity/1  specificity, the ratio of
FIT positivity in patients who have lesions to that in pa-
tients who do not) in detecting adenomas less than 10 mm is
only 1, indicating a FIT-positivity rate not different from
chance occurrence. In fact, in a recent large-scale study
from the USA, even using a multitarget stool DNA test,
which is composed of quantitative molecular assays for
KRAS mutations, aberrant NDRG4 and BMP3 methylation, b-
actin, as well as FIT, the sensitivity for detecting advanced
adenomas or sessile serrated polyps measuring 1 cm is
42.4%, which is still not satisfactory for mass screening.Using FIT alone, the sensitivity further declines to 23.8%
[8]. Therefore, the currently available stool-sample-based
screening tests remain limited in the detection of colonic
adenomas; CRC is our main target. In the mass-screening
program, repeated screening (e.g., every 2 years in
Taiwan) is essential for the detection of the CRC newly
developed from an adenoma when it starts to shed a
detectable amount of blood.
Qualitative versus quantitative FITs
After the introduction of the quantitative FIT, the optimal
cut-off hemoglobin concentration of FIT for a positive test
is under evaluation. In contrast to the qualitative FIT (OC-
Light test; Eiken Chemical Co., Tokyo, Japan) used in the
present study, quantitative FITs with either the OC-Sensor
test (Eiken Chemical Co.) or the HM-Jack test (Kyowa
Medex Co. Ltd, Tokyo, Japan) are now widely used in
Taiwan. When extrapolating the findings of diagnostic ac-
curacy studies to clinical practice, it should be recognized
that the cut-off concentration may be different between
FITs of the same brand and between FITs of different
brands. In the present study, the established cut-off con-
centration for the OC-Light test is 50 ng Hb/mL of buffer,
whereas that for the OC-Sensor test is generally set at
100 ng Hb/mL of buffer. Such hemoglobin concentrations in
a sampling device buffer may be unified into a standardized
reporting unit using hemoglobin concentration in feces, as
this study has shown. This proposal aims to improve the
comparability between the different brands of FIT and
decrease the complexity in interpreting their results. The
equation is as follows [9]:A lower cut-off concentration is reasonably associated
with a higher positive rate and higher sensitivity, but with a
lower specificity, and a greater number of colonoscopies
are performed. Similarly, increasing the number of FIT
samples for each screening is associated with a greater
sensitivity but a lower specificity. A previous study has
shown that the sensitivity and specificity for detecting CRC
were 65% and 94%, 82% and 92%, and 88% and 90%,
respectively, using the one-, two-, and three-sample
methods, respectively [10]. Such a tradeoff usually re-
quires sophisticated economic evaluation by taking into
account the actual costs and capacity of personnel to
perform endoscopy.
Sensitivity versus positive predictive value
From the perspective of patients undergoing screening, the
positive predictive value (PPV), i.e., the probability that
individuals with a positive FIT truly have the CRC, is the
most relevant indicator. The PPV is not only associated with
FIT performance, but also sensitive to the prevalence of
Editorial 71CRC in the target population. This relationship can be




Older age, male sex, cigarette smoking, obesity, a family
history of CRC, and a personal history of colonic neoplasms
are well-known risk factors. Individuals with more risk
factors will have a higher prevalence of CRC; when they
undergo FIT screening, their rate of positive results and PPV
will be higher. In the present study, the authors performed
a subgroup analysis according to age and found that the
PPVs were similar between groups of age 40e49 years and
50e75 years and between groups of age 40 years and 50
years, based on the index lesions of advanced neoplasms.
They suggested that earlier screening may be feasible for
individuals 40e49 years of age. Indeed, selection of some
high-risk individuals for an earlier screen is reasonable and
common in clinical practices; however, this should be
interpreted with great caution when age is used as the only
criterion for the policy-making judgment. In addition to the
concerns of statistical power, it should be clarified whether
their finding is attributed to a higher proportion of male
participants with risk factors in the younger age group. In a
recent study, Chang et al [12] have found that, in in-
dividuals aged 40e49 years, only men who smoke and have
metabolic syndrome have a higher risk of colorectal neo-
plasms, and so their diagnostic yields of screening tests may
increase.
Conclusion
Cumulative evidence has confirmed that FIT is a sensitive
screening test with the potential to decrease the mortality
of CRC when it is implemented at the population level.
Although the evaluation of FIT performance is undoubtedly
an important first step, one positive test is not equal to one
cancer detected. Many other important issues complicate
the screening process. To improve the effectiveness of our
national campaign against CRC, a step-by-step evaluation
of the process is needed.
Conflicts of interest
The author declares that he has no potential, perceived, or
real conflicts of interest.
References
[1] Chiu HM, Lee YC, Tu CH, Chen CC, Tseng PH, Liang JT, et al.
Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin
Gastroenterol Hepatol 2013;11:832e8.
[2] Chiang TH, Lee YC, Tu CH, Chiu HM, Wu MS. Performance of
the immunochemical fecal occult blood test in predicting le-
sions in the lower gastrointestinal tract. CMAJ 2011;183:
1474e81.
[3] Lee YC, Chiu HM, Chiang TH, Yen AMF, Chiu SYH, Chen SLS,
et al. Accuracy of faecal occult blood test and Helicobacter
pylori stool antigen test for detection of upper gastrointes-
tinal lesions. BMJ Open 2013;3:e003989.
[4] Yen AM, Chen SL, Chiu SY, Fann JC, Wang PE, Lin SC, et al. A
new insight into fecal hemoglobin concentration-dependent
predictor for colorectal neoplasia. Int J Cancer 2014;135:
1203e12.
[5] Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy
of fecal immunochemical tests for colorectal cancer: sys-
tematic review and meta-analysis. Ann Intern Med 2014;
160:171e81.
[6] Chen YY, Chen TH, Su MY, Ning HC, Kuo CJ, Lin WP, et al.
Accuracy of immunochemical fecal occult blood test for
detecting colorectal neoplasms in individuals undergoing
health check-ups. Adv Dig Med 2014;1:74e9.
[7] Church TR, Ederer F, Mandel JS. Fecal occult blood screening
in the Minnesota study: sensitivity of the screening test. J Natl
Cancer Inst 1997;89:1440e8.
[8] Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P,
Lidgard GP, et al. Multitarget stool DNA testing for colorectal-
cancer screening. N Engl J Med 2014;370:1287e97.
[9] Fraser CG, Allison JE, Halloran SP, Young GP, Expert Working
Group on Fecal Immunochemical Tests for Hemoglobin, Colo-
rectal Cancer Screening Committee, World Endoscopy Orga-
nization. A proposal to standardize reporting units for fecal
immunochemical tests for hemoglobin. J Natl Cancer Inst
2012;104:810e4.
[10] Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. A
quantitative immunochemical fecal occult blood test for
colorectal neoplasia. Ann Intern Med 2007;146:244e55.
[11] Altman DG, Bland JM. Diagnostic tests 2: predictive values.
BMJ 1994;309:102.
[12] Chang LC, Wu MS, Tu CH, Lee YC, Shun CT, Chiu HM.
Metabolic syndrome and smoking may justify earlier colo-
rectal cancer screening in men. Gastrointest Endosc 2014;
79:961e9.
Yi-Chia Lee*
National Taiwan University Hospital, Taipei, Taiwan
Graduate Institute of Epidemiology and Preventive
Medicine, College of Public Health, National Taiwan
University, Taipei, Taiwan
*Department of Internal Medicine,
National Taiwan University Hospital,
Number 7, Chung-Shan South Road, Taipei 10002, Taiwan
E-mail address: yichialee@ntu.edu.tw
23 May 2014
